Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus

Marcia Venegas-Pont, Julio Sartori Valinotti, Christine Maric, Lorraine C. Racusen, Porter H. Glover, Gerald R. McLemore, Allison V. Jones, Jane F. Reckelhoff, Michael J. Ryan

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Women with systemic lupus erythematosus (SLE) exhibit a high prevalence of hypertension and renal injury. Rosiglitazone (Rosi), a peroxisome proliferator activator receptor gamma (PPARγ) agonist, has renal protective and antihypertensive effects. We tested whether Rosi ameliorates hypertension and renal injury in a female mouse model of SLE (NZBWF1). Thirty-week-old SLE and control (NZW/LacJ) mice (n ≥ 6/group) were fed Rosi (5 mg·kg -1 ·day-1 in standard chow) or standard chow for 4 wk. SLE mice had increased blood pressure (BP in mmHg) compared with controls (139 ± 4 vs. 111 ± 4, P < 0.05). Rosi treatment lowered BP in SLE mice (127 ± 4, P < 0.05) but not in controls (111 ± 4). Urinary albumin (μg/mg creatinine) was increased in SLE mice compared with controls (12,396 ± 6,525 vs. 50 ± 6) and reduced with Rosi treatment (148 ± 117). Glomerulosclerosis (% of glomeruli with sclerosis) was reduced in Rosi-treated SLE mice (4.2 ± 1.6 vs. 0.4 ± 0.3, P < 0.05). Renal monocyte/ macrophage numbers (cell number/1,320 points counted) were reduced in SLE mice treated with Rosi (32.6 ± 11.0 vs. 10.6 ± 3.6, P < 0.05) but unchanged in controls (3.7 ± 1.6 vs. 3.7 ± 2.0). Renal osteopontin expression, a cytokine-regulating macrophage recruitment, was reduced in Rosi-treated SLE mice. Urinary endothelin (in pg/mg creatinine) was increased in SLE mice compared with controls (1.9 ± 0.59 vs. 0.6 ± 0.04, P < 0.05) and reduced in SLE mice treated with Rosi (0.8 ± 0.11, P < 0.05). PPARγ protein expression in the renal cortex was significantly lower in SLE mice compared with controls and was unaffected by Rosi. These data suggest that Rosi may be an important therapeutic option for the treatment of SLE hypertension and renal injury.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Regulatory Integrative and Comparative Physiology
Volume296
Issue number4
DOIs
StatePublished - Apr 1 2009
Externally publishedYes

Fingerprint

rosiglitazone
Systemic Lupus Erythematosus
Blood Pressure
Kidney
Wounds and Injuries
Renal Hypertension
Peroxisome Proliferators
Creatinine

Keywords

  • Endothelin
  • Glomerulosclerosis
  • Inflammation
  • Lupus
  • Proliferator activated receptor gamma

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus. / Venegas-Pont, Marcia; Sartori Valinotti, Julio; Maric, Christine; Racusen, Lorraine C.; Glover, Porter H.; McLemore, Gerald R.; Jones, Allison V.; Reckelhoff, Jane F.; Ryan, Michael J.

In: American Journal of Physiology - Regulatory Integrative and Comparative Physiology, Vol. 296, No. 4, 01.04.2009.

Research output: Contribution to journalArticle

Venegas-Pont, Marcia ; Sartori Valinotti, Julio ; Maric, Christine ; Racusen, Lorraine C. ; Glover, Porter H. ; McLemore, Gerald R. ; Jones, Allison V. ; Reckelhoff, Jane F. ; Ryan, Michael J. / Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus. In: American Journal of Physiology - Regulatory Integrative and Comparative Physiology. 2009 ; Vol. 296, No. 4.
@article{ca8825956eb74924b3bbc185fde85d2c,
title = "Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus",
abstract = "Women with systemic lupus erythematosus (SLE) exhibit a high prevalence of hypertension and renal injury. Rosiglitazone (Rosi), a peroxisome proliferator activator receptor gamma (PPARγ) agonist, has renal protective and antihypertensive effects. We tested whether Rosi ameliorates hypertension and renal injury in a female mouse model of SLE (NZBWF1). Thirty-week-old SLE and control (NZW/LacJ) mice (n ≥ 6/group) were fed Rosi (5 mg·kg -1 ·day-1 in standard chow) or standard chow for 4 wk. SLE mice had increased blood pressure (BP in mmHg) compared with controls (139 ± 4 vs. 111 ± 4, P < 0.05). Rosi treatment lowered BP in SLE mice (127 ± 4, P < 0.05) but not in controls (111 ± 4). Urinary albumin (μg/mg creatinine) was increased in SLE mice compared with controls (12,396 ± 6,525 vs. 50 ± 6) and reduced with Rosi treatment (148 ± 117). Glomerulosclerosis ({\%} of glomeruli with sclerosis) was reduced in Rosi-treated SLE mice (4.2 ± 1.6 vs. 0.4 ± 0.3, P < 0.05). Renal monocyte/ macrophage numbers (cell number/1,320 points counted) were reduced in SLE mice treated with Rosi (32.6 ± 11.0 vs. 10.6 ± 3.6, P < 0.05) but unchanged in controls (3.7 ± 1.6 vs. 3.7 ± 2.0). Renal osteopontin expression, a cytokine-regulating macrophage recruitment, was reduced in Rosi-treated SLE mice. Urinary endothelin (in pg/mg creatinine) was increased in SLE mice compared with controls (1.9 ± 0.59 vs. 0.6 ± 0.04, P < 0.05) and reduced in SLE mice treated with Rosi (0.8 ± 0.11, P < 0.05). PPARγ protein expression in the renal cortex was significantly lower in SLE mice compared with controls and was unaffected by Rosi. These data suggest that Rosi may be an important therapeutic option for the treatment of SLE hypertension and renal injury.",
keywords = "Endothelin, Glomerulosclerosis, Inflammation, Lupus, Proliferator activated receptor gamma",
author = "Marcia Venegas-Pont and {Sartori Valinotti}, Julio and Christine Maric and Racusen, {Lorraine C.} and Glover, {Porter H.} and McLemore, {Gerald R.} and Jones, {Allison V.} and Reckelhoff, {Jane F.} and Ryan, {Michael J.}",
year = "2009",
month = "4",
day = "1",
doi = "10.1152/ajpregu.90992.2008",
language = "English (US)",
volume = "296",
journal = "American Journal of Physiology",
issn = "0363-6119",
publisher = "American Physiological Society",
number = "4",

}

TY - JOUR

T1 - Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus

AU - Venegas-Pont, Marcia

AU - Sartori Valinotti, Julio

AU - Maric, Christine

AU - Racusen, Lorraine C.

AU - Glover, Porter H.

AU - McLemore, Gerald R.

AU - Jones, Allison V.

AU - Reckelhoff, Jane F.

AU - Ryan, Michael J.

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Women with systemic lupus erythematosus (SLE) exhibit a high prevalence of hypertension and renal injury. Rosiglitazone (Rosi), a peroxisome proliferator activator receptor gamma (PPARγ) agonist, has renal protective and antihypertensive effects. We tested whether Rosi ameliorates hypertension and renal injury in a female mouse model of SLE (NZBWF1). Thirty-week-old SLE and control (NZW/LacJ) mice (n ≥ 6/group) were fed Rosi (5 mg·kg -1 ·day-1 in standard chow) or standard chow for 4 wk. SLE mice had increased blood pressure (BP in mmHg) compared with controls (139 ± 4 vs. 111 ± 4, P < 0.05). Rosi treatment lowered BP in SLE mice (127 ± 4, P < 0.05) but not in controls (111 ± 4). Urinary albumin (μg/mg creatinine) was increased in SLE mice compared with controls (12,396 ± 6,525 vs. 50 ± 6) and reduced with Rosi treatment (148 ± 117). Glomerulosclerosis (% of glomeruli with sclerosis) was reduced in Rosi-treated SLE mice (4.2 ± 1.6 vs. 0.4 ± 0.3, P < 0.05). Renal monocyte/ macrophage numbers (cell number/1,320 points counted) were reduced in SLE mice treated with Rosi (32.6 ± 11.0 vs. 10.6 ± 3.6, P < 0.05) but unchanged in controls (3.7 ± 1.6 vs. 3.7 ± 2.0). Renal osteopontin expression, a cytokine-regulating macrophage recruitment, was reduced in Rosi-treated SLE mice. Urinary endothelin (in pg/mg creatinine) was increased in SLE mice compared with controls (1.9 ± 0.59 vs. 0.6 ± 0.04, P < 0.05) and reduced in SLE mice treated with Rosi (0.8 ± 0.11, P < 0.05). PPARγ protein expression in the renal cortex was significantly lower in SLE mice compared with controls and was unaffected by Rosi. These data suggest that Rosi may be an important therapeutic option for the treatment of SLE hypertension and renal injury.

AB - Women with systemic lupus erythematosus (SLE) exhibit a high prevalence of hypertension and renal injury. Rosiglitazone (Rosi), a peroxisome proliferator activator receptor gamma (PPARγ) agonist, has renal protective and antihypertensive effects. We tested whether Rosi ameliorates hypertension and renal injury in a female mouse model of SLE (NZBWF1). Thirty-week-old SLE and control (NZW/LacJ) mice (n ≥ 6/group) were fed Rosi (5 mg·kg -1 ·day-1 in standard chow) or standard chow for 4 wk. SLE mice had increased blood pressure (BP in mmHg) compared with controls (139 ± 4 vs. 111 ± 4, P < 0.05). Rosi treatment lowered BP in SLE mice (127 ± 4, P < 0.05) but not in controls (111 ± 4). Urinary albumin (μg/mg creatinine) was increased in SLE mice compared with controls (12,396 ± 6,525 vs. 50 ± 6) and reduced with Rosi treatment (148 ± 117). Glomerulosclerosis (% of glomeruli with sclerosis) was reduced in Rosi-treated SLE mice (4.2 ± 1.6 vs. 0.4 ± 0.3, P < 0.05). Renal monocyte/ macrophage numbers (cell number/1,320 points counted) were reduced in SLE mice treated with Rosi (32.6 ± 11.0 vs. 10.6 ± 3.6, P < 0.05) but unchanged in controls (3.7 ± 1.6 vs. 3.7 ± 2.0). Renal osteopontin expression, a cytokine-regulating macrophage recruitment, was reduced in Rosi-treated SLE mice. Urinary endothelin (in pg/mg creatinine) was increased in SLE mice compared with controls (1.9 ± 0.59 vs. 0.6 ± 0.04, P < 0.05) and reduced in SLE mice treated with Rosi (0.8 ± 0.11, P < 0.05). PPARγ protein expression in the renal cortex was significantly lower in SLE mice compared with controls and was unaffected by Rosi. These data suggest that Rosi may be an important therapeutic option for the treatment of SLE hypertension and renal injury.

KW - Endothelin

KW - Glomerulosclerosis

KW - Inflammation

KW - Lupus

KW - Proliferator activated receptor gamma

UR - http://www.scopus.com/inward/record.url?scp=65949088801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65949088801&partnerID=8YFLogxK

U2 - 10.1152/ajpregu.90992.2008

DO - 10.1152/ajpregu.90992.2008

M3 - Article

C2 - 19193937

AN - SCOPUS:65949088801

VL - 296

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6119

IS - 4

ER -